Branded Generic Market

Global Branded Generic Market Size

The global branded generic market was valued at USD 38,612.61 million in 2025, is estimated to reach USD 40,621 million in 2026, and is projected to reach USD 60,936 million by 2034, growing at a CAGR of 5.20% from 2026 to 2034.

The market has had substantial growth, which is mostly attributable to the patent exclusivity of innovator pharmaceuticals expiring, which gives generic manufacturers a great opportunity to introduce goods at a lower price.

MARKET DRIVERS

One of the main factors boosting the global growth of the branded generic industry is the increased prevalence of chronic diseases. It is projected that the increasing burden of infectious and non-infectious diseases, as well as the growing population, which is more prone to chronic disorders including hypertension, diabetes, and obesity, will have a favorable effect on growth. In 2022, there were 560 million diabetic patients worldwide. According to International Diabetes Federation data from 2022, there will be 620 million people worldwide suffering from diabetes by 2028. As a result, businesses are introducing novel products to expand their product lines, which is causing the market to grow faster than anticipated during the anticipated period. People's changing lifestyles, poor diets, and lack of physical activity are all contributing to an increase in chronic disease. Additionally, patients with chronic diseases must take proper medication daily, which necessitates medication at a reasonable cost. As a result, people with middle- and lower-class incomes purchase generic drugs at lower prices, which is one of the primary factors driving the growth of the industry.

The rising need for affordable healthcare solutions, which is accelerating the market expansion of generics in developing and wealthy nations, is another driver promoting market growth. These medications offer an excellent balance between cost-effectiveness and quality, appealing to both patients and medical professionals. Thus, the fact that branded generics are affordable for every person stimulates demand during the anticipated term. Another significant driver propelling the market expansion during the anticipated period is the poor financial situation of many individuals in various nations, and the need for quality medications at cost-effective prices among those who must take daily medications.

Another significant factor driving the market growth of branded generic products is the rising government initiative to promote generic products and the increasing penetration of branded generic pharmaceuticals. Increased government efforts to increase public awareness will result in a major expansion of the market for branded generics. The low cost of generic medications makes them more affordable for patients and lowers the per-capita cost of healthcare.

Increased cardio metabolic risk factors, an increase in cancer cases, increased government efforts to promote generic products, and patent expiration providing opportunities for generic manufacturers to introduce products at reduced rates are a few of the major factors driving the growth of the branded generic market. This factor boosted the branded generic market during the forecasted period.

MARKET RESTRAINTS

Although numerous factors are raising the demand for the branded generic market, there are also some factors limiting its expansion. The supply chain efficiency, distribution channels, and overall revenue growth of the branded generic market are constrained by social and ethical concerns, economic policies, trade effects, legal situations, and demographic changes. Healthcare authorities' strict regulatory requirements, which make it difficult for newly branded generic products to enter the market. Additionally, the lack of efficient quality control procedures and the availability of inexpensive alternatives may undermine patient and healthcare professional confidence, which restrains market expansion.

The competition from brand-name drugs is another factor that prevents the market from expanding. The regulatory barrier is one of the main key restraining factors because many healthcare authorities have set standards for processing and maintaining the quality of drugs due to quality factors many healthcare authorities only rely on branded drugs instead of generic drugs.

REPORT COVERAGE

SEGMENT ANALYSIS

By Therapeutic Application Insights

The oncology segment dominates the market with the fastest CAGR throughout the anticipated period based on therapeutic application. The oncology section is predicted to expand at the highest CAGR of 7.02% by 2028 due to the patent expiration of significant medications in this field. The market's expansion was significantly influenced by the increased occurrence of illness. According to WCRF International, there will be 19.2 million new instances of cancer worldwide in 2022, with 8.5 million cases affecting women and 9.4 million cases affecting males. As a result, this market segment has the fastest CAGR over the anticipated time.

At a strong CAGR during the anticipated period, the diabetes sector will continue to dominate the market. Changes in lifestyle, poor diet, unbalanced mental health, and lack of physical activity are some of the main factors of the rise in diabetes incidence globally. More than 130 million adult people had diabetes in 2022, according to the CDC's National Diabetes Statistics Report. This will raise demand for medication, making this segment the one that will dominate the branded generic market during the forecasted period.

By Drug Class Insights

Anti-hypertensive medications dominate the market with the fastest CAGR during the anticipated period, according to drug classes. The anti-hypertensive sector dominated the market in 2022 with a revenue share of 16.69% and is anticipated to continue dominating the market during the forecast period due to an increase in ANDA approval and due to acute and chronic disease, product introductions over the previous few years.

Due to increased investment to create complicated or value-added generics, the hormone segment is also predicted to rise rapidly during the forecasted period. The prevalence of metabolic illnesses has increased as a result of an increasingly sedentary lifestyle. Due to some of these factors, the hormone sector is expected to lead the market throughout the anticipated period because this illness includes thyroid and sex hormone imbalance.

By Formulation Type Insights

The oral formulation segment dominates the market with the fastest CAGR over the anticipated period, according to the formulation type. The oral segment accounted for the greatest revenue share of 60.04% in the branded generic market in 2022 due to numerous advantages such as simplicity of administration and the lack of nursing requirements, the oral formulation resulting in improved patient acceptability and compliance. Because oral medications are easy to administer and because sweeteners and color coatings make tablets and capsules more palatable, the oral formulation sector is expected to dominate the market during the anticipated period.

Due to the rising frequency of target diseases like cancer, hepatitis C, and multiple sclerosis as well as the consequent high demand for generic injectable, the parenteral segment is anticipated to have the quickest growth throughout the anticipated period. This segment, which includes things like insulin, peptide hormones, and small-molecule antibiotics, among others, is anticipated to develop at the highest CAGR of 7.9% for the projected year.

By Distribution Channel Insights

Based on the distribution channel during the anticipated period, the retail pharmacy sector is expected to dominate the market. In 2022, the retail pharmacy distribution sector had the largest market share (59.8%), and this trend is anticipated to hold true throughout the forecast period. The market for branded generics is estimated to develop at the highest CAGR during the projected period due to the rising burden of chronic diseases and various types of discounts provided by retail pharmacies.

Online pharmacies are anticipated to expand during the projection period at a strong CAGR. Manufacturers are establishing relationships with online pharmacies in response to the growth of e-commerce, and the pandemic scenario has also benefited this category because customers bought branded generics from these establishments. As a result, this segment is anticipated to rule the market by 2028.

REGIONAL ANALYSIS

Based on Region, during the anticipated timeframe, the North American region will dominate the branded generic market. In 2022, this region held a share of 19.69% of the global market, and over the foreseeable future, it is anticipated that this region will continue to expand at a stable rate. The high penetration of branded generic medications, the rising population and disease load, and other factors all contribute to the market's expansion in this area.

The Asia-pacific region is also expected to grow at a CAGR of 6.9% during the forecasted period. The expanding market share of the products in the countries like China, Japan, and India drives the market growth during the forecasted period.

The western and Eastern Europe is expected to dominate the market at a steady CAGR during the projection period. Due to digital technology, the accessibility provided by online purchases of branded generic drugs, flexibility, and the offer-discount provided by online pharmacies attract patients to buy drugs online are the major driver driving the growth of the market in this region.

The increasing incidence of individuals with Alzheimer’s disease, osteoarthritis, and rheumatoid arthritis and the increasing number of patent expiration are some of the key factors stimulating the growth of the market in this region.

The Middle East and Africa are also expected to grow at a steady CAGR, by introducing new technologies and features, the increasing number of vendors in the Middle East and Africa for branded generic market causes domination by this region during the forecasted period.

KEY MARKET PLAYERS

The prominent market players in the global branded generic market include

• Lupin
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories
• GlaxoSmithKline Inc.
• Apotex Inc.
• Pfizer Inc.
• Viatris Inc.

GLOBAL BRANDED GENERIC MARKET NEWS

• In June 25 2023, Indies Pharma introduces new branded generic drugs to the Jamaican market.
• In July 2022, Lupin, an India-based pharmaceutical company offering branded and generic formulations, biosimilars, and active pharmaceutical ingredients (APIs), acquired Southern Cross Pharma Pvt Ltd (SCP) for an undisclosed amount. Through this acquisition, Generic Health, an Australia-based wholly-owned subsidiary of global pharma major Lupin Limited, will have access to more than 60 registered products with approximately USD 22 million in sales.

MARKET SEGMENTATION

This global branded generic market research report is segmented and sub-segmented into the following categories.

By Therapeutic Application

• Oncology
• Cardiovascular disease
• Diabetes
• Neurology
• Dermatology disease
• Gastro-intestinal disease
• Analgesic and anti-inflammatory

By Drug class

• Alkylating agent
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid-lowering drugs
• Antipsychotics
• Antiepileptic
• Others

By Formulation type

• Oral
• Parenteral
• Topical
• Others

By Distribution channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Drug stores

By Region

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East and Africa